SCHEMBL4284818

SCHEMBL4284818

Cc1cc(N)cc(Nc2nccc(Oc3ccc4[nH]ccc4c3)n2)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SYK P43405 6/20 0.45
JAK2 O60674 1/20 0.42
KCNH2 Q12809 1/20 0.41
SCN5A Q14524 1/20 0.41
SCN9A Q15858 1/20 0.41
KDR P35968 8/20 0.41
FGFR1 P11362 1/20 0.41
FLT1 P17948 1/20 0.41
FLT4 P35916 1/20 0.41
FLT3 P36888 1/20 0.41
MERTK Q12866 1/20 0.41
NTRK2 Q16620 1/20 0.41
IGF1R P08069 1/20 0.39
ULK1 O75385 1/20 0.39
SRC P12931 1/20 0.39
MAPK14 Q16539 1/20 0.39
PRKD1 Q15139 1/20 0.38
EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4288245 0.85 CDK5 (0.49) SYKJAK2KDRFGFR1FLT1
SCHEMBL4287689 0.85 KDR (0.50) SYKKDRFGFR1FLT1FLT4
SCHEMBL13805488 0.84 SYK (0.50) SYKJAK2KCNH2SCN5ASCN9A
SCHEMBL4287649 0.82 SYK (0.47) SYKJAK2KCNH2SCN5ASCN9A
SCHEMBL13805489 0.82 ABL1 (0.44) SYKJAK2SCN9AKDRFGFR1
SCHEMBL4287622 0.82 SYK (0.48) SYKJAK2SCN9AKDRFGFR1
SCHEMBL4281016 0.82 KDR (0.54) SYKJAK2KDRFGFR1FLT1
SCHEMBL4284784 0.80 SYK (0.50) SYKJAK2KDRFGFR1FLT1
SCHEMBL4279518 0.80 SYK (0.48) SYKJAK2KCNH2SCN5ASCN9A
SCHEMBL4279265 0.79 SYK (0.46) SYKJAK2KDRFGFR1FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US claimed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP claimed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO claimed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149467-A1 Tyrosine Kinase Inhibitors ABL1, MET, ERBB2 SYK 86/4885JAK2 14/4885KCNH2 4503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.